Trial: 201902119

Randomized phase 2 clinical trial of nab-paclitaxel + MEDI4736 (durvalumab) + neoantigen vaccine vs. nab-paclitaxel + MEDI4736 (durvalumab) in patients with metastatic triple negative breast cancer

Phase

II

Principal Investigator

Gillanders, William

Disease Site

Breast

Learn more about this study at: clinicaltrials.gov